Save on Delstrigo with Coupons, Discounts & Savings Programs

Delstrigo is the brand name for doravirine, lamivudine, and tenofovir disoproxil fumarate and is available as an oral tablet.

Delstrigo is available as an oral tablet that contains 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of
tenofovir disoproxil fumarate.

Delstrigo is a HIV ARV combo and is used for the following:

• People who have never taken HIV ARVs
• People who are well controlled on an HIV ARV regimen, have a viral load of less than 50, and want to switch regimens

Delstrigo is an HIV ARV combination medication. It contains three medications that prevent HIV from infecting your cells and making copies of itself. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It stops reverse transcriptase, an important enzyme needed for the virus to make DNA (genetic material). Lamivudine and tenofovir are nucleoside reverse transcriptase inhibitors (NRTIs). They insert themselves into the virus’ DNA and stop the DNA-making process.

Delstrigo is typically taken as 1 tablet by mouth once a day with or without food. Each tablet contains 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir.

Delstrigo is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. Delstrigo is contraindicated when co-administered with drugs that
are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of Delstrigo.
Delstrigo is contraindicated in patients with a previous
hypersensitivity reaction to lamivudine.

Common side effects of Delstrigo:

• Dizziness
• Nausea
• Abnormal dreams

Serious side effects are rare with Delstrigo. Contact your healthcare provider immediately if you experience any of the following.

• Liver problems if you have hepatitis B and suddenly stop taking Delstrigo: fever, tiredness, nausea, vomiting, stomach pain, dark urine, yellowing of your skin or eyes
• Kidney problems: swelling in your legs and feet, difficulty urinating, confusion, bone or muscle pain, pain in the arms or legs

The following medications may interact with Delstrigo:

• Because Delstrigo is a complete regimen, co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended
• Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions

Merck & Co., Inc.

It is not known if Delstrigo can harm your unborn baby.
Delstrigo should only be used during pregnancy if the benefit to you is worth the possible risk to your baby. There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to Delstrigo during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.

• Doravirine/Lamivudine/Tenofovir